Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : Dr. Paul Janssen Award for Biomedical Research Issues 2018 Call for Nominations to Celebrate Champions of Science

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2018 | 09:01pm CEST

NEW BRUNSWICK, N.J., Jan. 3, 2018 /PRNewswire/ -- Nominations are now being accepted for the 2018 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates today's most dedicated researchers and champions of science whose basic or clinical discoveries have made, or have the potential to make, significant contributions toward improving human health. Nominations will be accepted until February 28, 2018 at www.pauljanssenaward.com for consideration by an independent selection committee of world-renowned scientists. A $200,000 cash prize will be awarded to the scientist or group of scientists receiving the Award.

The Dr. Paul Janssen Award for Biomedical Research honors Dr. Paul Janssen (1926-2003), one of the most productive pharmaceutical scientists of the 20th century, who was responsible for breakthrough treatments in key disease areas including pain management, psychiatry, infectious disease and gastroenterology. Janssen founded Janssen Pharmaceutica, N.V., now part of the Johnson & Johnson Family of Companies (NYSE: JNJ).

"Behind every discovery that holds the promise for saving and improving lives are the scientists who pursue a vision and work tirelessly for many years to make it all possible," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. "We are proud to honor the legacy of Dr. Paul by recognizing the outstanding researchers and champions of science who make a lasting impact on our world."

In 2017, the Dr. Paul Janssen Award recognized trailblazing scientist Douglas Wallace, Ph.D., of the Children's Hospital of Philadelphia, for pioneering the field of mitochondrial genetics and its application to the study of disease, aging, and patterns of human migration.

"Scientific research is crucial to advancing our understanding of the mechanisms underlying human health and disease," said David Julius, Ph.D., Professor and Chair of the Department of Physiology at the University of California, San Francisco, and Chair of the 2018 Dr. Paul Janssen Award selection committee. "The selection committee encourages nominations of scientists from academia, industry, government and scientific institutions around the world who champion science through the work they do everyday and exemplify the leadership and passion of Dr. Paul."

Previous Award winners include:

  • 2017 –  Douglas Wallace, Ph.D.
  • 2016 – Yoshinori Ohsumi, Ph.D., Nobel Laureate
  • 2015 – Bert Vogelstein, M.D.
  • 2014 – Emmanuelle Charpentier, Ph.D. and Jennifer Doudna, Ph.D.
  • 2013 – David Julius, Ph.D.
  • 2012 – Victor Ambros, Ph.D., and Gary Ruvkun, Ph.D.
  • 2011 – Napoleone Ferrara, M.D.
  • 2010 – Anthony S. Fauci, M.D. and Erik De Clercq, M.D., Ph.D.,
  • 2009– Axel Ullrich, Ph.D.
  • 2008 – Professor Marc Feldmann, FMedSci, FAA, FRS, Emeritus Professor and Sir Ravinder Maini, FRCP, FMedSci, FRS
  • 2006 – Craig Mello, Ph.D., Nobel Laureate

To learn more about past Dr. Paul Janssen Award winners, visit www.pauljanssenaward.com.

The 2018 Dr. Paul Janssen Award winner will be announced in spring 2018.

About The Dr. Paul Janssen Award for Biomedical Research
Established by Johnson & Johnson, The Dr. Paul Janssen Award salutes champions of science and the most passionate and creative scientists in basic or clinical research whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. The Award is named after the scientist who founded Janssen Pharmaceutica, N.V. in 1953. Known to his colleagues as "Dr. Paul," Janssen helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization's list of essential medicines. In 1961, Janssen Pharmaceutica, N.V. joined the Johnson & Johnson Family of Companies. Janssen's legacy continues to inspire Johnson & Johnson and its commitment to finding innovative cures for unmet medical needs. Visit www.pauljanssenaward.com for more information.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 132,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

 (PRNewsfoto/Johnson & Johnson)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/dr-paul-janssen-award-for-biomedical-research-issues-2018-call-for-nominations-to-celebrate-champions-of-science-300577115.html

SOURCE Johnson & Johnson


© PRNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04/21JOHNSON & JOHNSON : J&J, BMS Team Up on Cardiovascular Therapies
AQ
04/20GENMAB : Announces Net Sales of DARZALEX for First Quarter of 2018
AQ
04/20JOHNSON & JOHNSON : Reports 2018 First-Quarter Results
AQ
04/20JOHNSON & JOHNSON : Janssen Announces Worldwide Development and Commercializatio..
AQ
04/20JOHNSON & JOHNSON : Janssen Pharmaceutical - Newly Published Phase 2 Study Found..
AQ
04/20JOHNSON & JOHNSON : Small biotech companies dominate the pipeline for Microbiome..
AQ
04/20JOHNSON & JOHNSON : Kentucky sues opioid manufacturers
AQ
04/20JOHNSON & JOHNSON : BioCentury - BenevolentAI raises $115M
AQ
04/19JOHNSON & JOHNSON : - Newly Published Phase 2 study Found Esketamine Demonstrate..
AQ
04/19JOHNSON & JOHNSON : Studies offer hope of HIV vaccine
AQ
More news
News from SeekingAlpha
04/21STOCKS TO WATCH : Earnings Blockbusters And Trump Talks Drug Prices 
04/21THE PASSIVE DGI CORE PORTFOLIO : Income, Safety, And Growth 
04/20Rising Inflationary Expectations Cap Equities 
04/20IBM, Exxon, J&J among expected dividend hikes next week 
04/19JOHNSON & JOHNSON : Steady As She Goes